Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. BA
3. AVGO
4. HOOD
5. STX
6. SPY
7. CDNS
8. ANT
9. META
10. RCL

Go back to Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

Protagonist Therapeutics (PTGX) Misses Q4 EPS by 10c, Revenues Miss

March 12, 2019 4:05 PM EDT

Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 EPS of ($0.57), $0.10 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $2.35 million versus the consensus estimate of $4.83 million.

"We continue to advance three different clinical development candidates discovered from our proprietary peptide engineering platform and have sufficient financial resources to support these... More